ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2026
Aspirin (Acetylsalicylic Acid) Exerts Antineoplastic Effects on Bile Duct Carcinoma Cells Through Modulation of COX-2/ EGFR, AMPK, and IGF-1R Signaling Pathways.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Bile duct carcinoma (BDC) is a highly aggressive malignancy. While epidemiological evidence suggests that acetylsalicylic acid (ASA [aspirin]) reduces BDC risk, the underlying molecular mechanisms have not been fully elucidated. This investigation explored the antineoplastic mechanisms of ASA in BDC cells. Materials and Methods: The human BDC cell line SNU-245 was used in all experiments. Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, whereas apoptosis and caspase-3 levels were evaluated using enzyme-linked immunosorbent assay. Protein expression was analyzed using Western blotting and immunofluorescence. Functional pathway interactions were investigated using siRNA-mediated gene silencing. Results: ASA reduced cell viability and increased apoptosis markers, accompanied by increased Bax and p53 expression and decreased Bcl-2 levels. ASA treatment reduced cyclooxygenase-2 (COX-2) expression and decreased epidermal growth factor receptor (EGFR)levels. COX-2 knockdown markedly attenuated deoxycholic acid (DCA)-induced EGFR phosphorylation, whereas EGFR silencing partially reduced DCA-induced COX-2 expression. These results suggest reciprocal signaling interactions, with COX-2 exerting a relatively stronger upstream influence. ASA increased phosphorylation of AMP-activated protein kinase at threonine 172 (AMPKᵀʰʳ¹⁷²) and reduced insulin like growth factor-1 receptor (IGF-1R)/insulin receptor substrate-1 (IRS-1) signaling and decreased mammalian target of rapamycin (mTOR) phosphorylation. ASA also attenuated epidermal growth factor (EGF)-induced changes in epithelial-mesenchymal transition- related markers, including preservation of E-cadherin and reduction of N-cadherin expression. Conclusion: In this in vitro model, ASA exposure was associated with coordinated modulation of multiple cell-survival-related signaling pathways in BDC cells, including COX-2/EGFR signaling, AMPK activation, and IGF-1R-mediated mTOR regulation. These findings provide mechanistic insight into the potential antineoplastic effects of ASA and support further translational studies in BDC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.